Abstract
* The Food and Drug Administration has revised the labeling for saxagliptin (Onglyza) and alogliptin (Nesina), two dipeptidyl peptidase-4 inhibitors used in the treatment of type 2 diabetes, to include a warning that the drugs may increase the risk of heart failure.
* Nurses should assess for signs and symptoms of heart failure in patients receiving these drugs and inform patients about this potential adverse effect.